Benefits
Modest pain reduction in osteoarthritis trials (meta-analysis)
A meta-analysis of 3 RCTs (n=287, median 3-month duration) found rosehip powder produced an effect size of 0.37 (95% CI 0.13-0.60) for pain reduction vs placebo. Number needed to treat = 6. Effect size is small-to-moderate but consistent across trials — comparable to other dietary supplements for OA pain (e.g., glucosamine).
Improved joint mobility
Rosehip powder significantly improved hip flexion vs placebo over 4 months. Patient-reported global assessment of disease severity, pain on movement, and pain at rest all improved significantly.
Reduced NSAID consumption
In OA patients, the rosehip group had reduced consumption of analgesics and NSAIDs vs placebo. Patients reported improved general wellbeing alongside pain reduction.
Effect on inflammatory markers is unproven
Whether rosehip lowers inflammation in people is unsettled. A dedicated human study giving 10.5 grams of standardized rosehip powder daily for 4 weeks found no change in C-reactive protein and no change in antioxidant enzyme activity, in both rheumatoid arthritis patients and healthy controls. Some earlier reports described a CRP reduction, so the human evidence is inconsistent. GOPO inhibits neutrophil and monocyte chemotaxis in a test tube, but that is a laboratory finding, not a measured effect in people.
Mechanism of action
GOPO galactolipid anti-inflammatory action
GOPO — (2S)-1,2-di-O-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]-3-O-β-D-galactopyranosyl glycerol — is the principal anti-inflammatory active. In vitro, GOPO inhibits chemotaxis of peripheral blood neutrophils and monocytes, reducing inflammatory cell infiltration into joint tissue. This is preserved only in cold-processed rosehip preparations; standard hot extraction destroys it.
Cytokine and matrix metalloproteinase suppression
GOPO reduces production of NO, PGE2, TNF-α, IL-1β, IL-6, and IL-12 by human blood cells. It also suppresses gene expression of matrix metalloproteinases, aggrecanases, TNF-α, and NF-κB — pathways central to cartilage degradation in osteoarthritis.
Antioxidant lipid composition
Rosehip provides ω-3 (α-linolenic acid) and ω-6 (linoleic acid) PUFAs, plus triterpenic acids (betulinic, oleanolic, ursolic acid), high vitamin C content (rosehip is a traditional vitamin C source), lycopene, and various polyphenols. Combined antioxidant capacity supports joint tissue against oxidative damage from inflammation.
Clinical trials
Random-effects pooled analysis using REML methods (Christensen, Bartels, Altman, Astrup, Osteoarthritis Cartilage 16(9):965-972).
3 clinical trials, total n=287 OA patients (145 rosehip, 142 placebo). Median trial duration 3 months. All 3 trials supported by manufacturer Hyben-Vital International.
Pooled effect size for pain reduction = 0.37 (95% CI 0.13-0.60). Number needed to treat = 6. Authors concluded rosehip powder produces a small-to-moderate but statistically significant pain reduction in OA patients vs placebo. Manufacturer-funding noted as a study limitation.
Randomized, double-blind, placebo-controlled crossover trial (Winther, Apel, Scand J Rheumatol 34(4):302-8).
94 patients with osteoarthritis of the hip or knee. Crossover design with rosehip powder 5 g/day vs placebo for 3 months each, with washout period.
Rose-hip reduced WOMAC pain versus placebo by 3 weeks (p<0.014) and cut the use of rescue medication (p<0.027); WOMAC stiffness, disability, and global disease severity fell significantly only after 3 months. Pain relief was detectable from about 3 weeks.
Double-blind, placebo-controlled, randomized crossover trial (Rein, Kharazmi, Phytomedicine 11(5):383-91).
112 OA patients receiving 5 g/day Hyben Vital rosehip powder (standardized Rosa canina subspecies) vs placebo, each treatment for 3 months in a crossover design.
In the placebo-first arm rosehip reduced joint pain (p<0.0078) and stiffness (p<0.0025) and improved general wellbeing versus placebo; 66% of patients responded on rosehip versus 36% on placebo. In the rosehip-first arm placebo performed almost as well, which the authors attributed to a strong carryover effect. Uses the standardized cold-processed Rosa canina subspecies that preserves the GOPO galactolipid.